Bausch + Lomb and Clearside Biomedical Announce U.S. FDA Filing Acceptance for XIPERE

Friday, June 4 2021 | 15 h 48 min | News, Press Release

Bausch + Lomb, along with Clearside Biomedical, a biopharmaceutical company dedicated to developing and delivering treatments that restore and...

Read More

Bausch + Lomb Announces Results from First Phase 3 Trial of NOV03

Thursday, April 15 2021 | 09 h 33 min | Dry Eye, News, Press Release

Bausch + Lomb and Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced statistically significant...

Read More

Bausch Advances Novel Dry Eye Therapeutic to Phase 3

Tuesday, December 29 2020 | 07 h 28 min | Dry Eye, Latest News, News, Vision Science

Quebec based B+L has announced the second of two Phase 3 studies studies evaluating the investigational treatment NOV03 (perfluorohexyloctane) as a...

Read More

Bausch + Lomb Reports Nearly 27 Million Units of Contact Lens Materials Recycled

Monday, November 16 2020 | 10 h 26 min | News, Press Release

Bausch + Lomb announced that its exclusive ONE by ONE Recycling program has recycled nearly 27 million used contact lenses, top foils and...

Read More

Bausch Health to Acquire Option to Purchase Allegro Ophthalmics Assets

Tuesday, September 22 2020 | 10 h 04 min | News, Press Release

Bausch Health Companies Inc and Bausch + Lomb and Allegro Ophthalmics a privately held biopharmaceutical company focused on the development of novel...

Read More